AAPL297.49+3.19 (+1.08%) ▲|ABBV234.67-0.10 (-0.04%) ▼|ABT91.05+0.52 (+0.57%) ▲|ACN129.20+2.19 (+1.72%) ▲|ADBE198.64+1.21 (+0.61%) ▲|AMAT588.23+2.35 (+0.40%) ▲|AMD518.61-1.24 (-0.24%) ▼|AMGN351.39+4.38 (+1.26%) ▲|AMT175.05-4.33 (-2.41%) ▼|AMZN239.89+5.78 (+2.47%) ▲|AVGO384.07+3.92 (+1.03%) ▲|AXP342.76+4.98 (+1.47%) ▲|BA220.97+4.26 (+1.97%) ▲|BAC57.53-0.39 (-0.66%) ▼|BKNG182.11+13.17 (+7.80%) ▲|BLK982.52-32.81 (-3.23%) ▼|BMY55.09-0.44 (-0.79%) ▼|BNY145.28-2.01 (-1.36%) ▼|BRK-B497.07+4.26 (+0.86%) ▲|C143.40-1.57 (-1.08%) ▼|CAT1,000.35+16.11 (+1.64%) ▲|CL92.99+1.56 (+1.71%) ▲|CMCSA22.59-0.22 (-0.94%) ▼|COF201.81+4.00 (+2.02%) ▲|COP106.94-3.04 (-2.76%) ▼|COST961.11+3.43 (+0.36%) ▲|CRM154.33+0.91 (+0.59%) ▲|CSCO120.51-0.64 (-0.53%) ▼|CVS101.46-0.12 (-0.11%) ▼|CVX171.56-4.42 (-2.51%) ▼|DE609.73+17.79 (+3.01%) ▲|DHR187.97+9.00 (+5.03%) ▲|DIS102.29-1.24 (-1.20%) ▼|DUK125.18+0.13 (+0.10%) ▲|EMR142.20-0.94 (-0.66%) ▼|FDX313.03-4.21 (-1.33%) ▼|GD346.28-4.06 (-1.16%) ▼|GE367.55+11.08 (+3.11%) ▲|GEV1,063.92+28.94 (+2.80%) ▲|GILD125.47+0.42 (+0.34%) ▲|GM79.81+0.86 (+1.09%) ▲|GOOG347.89+1.81 (+0.52%) ▲|GOOGL348.75+2.66 (+0.77%) ▲|GS1,081.98-12.46 (-1.14%) ▼|HD340.26+15.81 (+4.87%) ▲|HON227.06+4.69 (+2.11%) ▲|IBM262.50-2.44 (-0.92%) ▼|INTC132.90+0.62 (+0.47%) ▲|INTU268.42+10.37 (+4.02%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ240.48+1.40 (+0.59%) ▲|JPM333.09-1.06 (-0.32%) ▼|KO81.24+0.93 (+1.15%) ▲|LIN521.77+9.51 (+1.86%) ▲|LLY1,109.80+2.72 (+0.25%) ▲|LMT493.50-10.17 (-2.02%) ▼|LOW220.88+7.34 (+3.44%) ▲|LRCX368.81-2.52 (-0.68%) ▼|MA493.69+5.62 (+1.15%) ▲|MCD274.21+2.55 (+0.94%) ▲|MDLZ62.15+1.09 (+1.79%) ▲|MDT80.65+0.02 (+0.02%) ▲|META560.77-1.43 (-0.25%) ▼|MMM167.73+5.89 (+3.64%) ▲|MO72.05+0.44 (+0.61%) ▲|MRK120.85+1.25 (+1.04%) ▲|MS221.35-4.69 (-2.07%) ▼|MSFT372.37-1.58 (-0.42%) ▼|MU1,037.63-14.15 (-1.34%) ▼|NEE86.79+0.36 (+0.41%) ▲|NFLX71.73-1.10 (-1.50%) ▼|NKE41.99-0.40 (-0.93%) ▼|NOW94.53-1.41 (-1.47%) ▼|NVDA199.69-0.32 (-0.16%) ▼|ORCL157.45-7.71 (-4.67%) ▼|PEP143.17+1.12 (+0.79%) ▲|PFE24.15-0.58 (-2.33%) ▼|PG153.09+2.23 (+1.47%) ▲|PLTR113.22-3.48 (-2.98%) ▼|PM178.59-0.10 (-0.06%) ▼|QCOM196.22-7.92 (-3.88%) ▼|RTX185.84-0.55 (-0.30%) ▼|SBUX103.92+2.87 (+2.84%) ▲|SCHW91.38-1.79 (-1.92%) ▼|SO94.74-0.20 (-0.21%) ▼|SPG218.90+2.16 (+1.00%) ▲|T22.41-0.41 (-1.78%) ▼|TMO489.11+19.76 (+4.21%) ▲|TMUS182.76-1.81 (-0.98%) ▼|TSLA378.32-3.29 (-0.86%) ▼|TXN303.86-0.50 (-0.16%) ▼|UBER74.45+4.78 (+6.86%) ▲|UNH406.37-2.89 (-0.70%) ▼|UNP260.55+1.94 (+0.75%) ▲|UPS105.24-0.59 (-0.56%) ▼|USB60.02-0.03 (-0.05%) ▼|V331.70+3.22 (+0.98%) ▲|VZ45.58-1.16 (-2.47%) ▼|WFC83.89-0.24 (-0.29%) ▼|WMT119.52+0.10 (+0.08%) ▲|XOM136.44-3.29 (-2.35%) ▼|AAPL297.49+3.19 (+1.08%) ▲|ABBV234.67-0.10 (-0.04%) ▼|ABT91.05+0.52 (+0.57%) ▲|ACN129.20+2.19 (+1.72%) ▲|ADBE198.64+1.21 (+0.61%) ▲|AMAT588.23+2.35 (+0.40%) ▲|AMD518.61-1.24 (-0.24%) ▼|AMGN351.39+4.38 (+1.26%) ▲|AMT175.05-4.33 (-2.41%) ▼|AMZN239.89+5.78 (+2.47%) ▲|AVGO384.07+3.92 (+1.03%) ▲|AXP342.76+4.98 (+1.47%) ▲|BA220.97+4.26 (+1.97%) ▲|BAC57.53-0.39 (-0.66%) ▼|BKNG182.11+13.17 (+7.80%) ▲|BLK982.52-32.81 (-3.23%) ▼|BMY55.09-0.44 (-0.79%) ▼|BNY145.28-2.01 (-1.36%) ▼|BRK-B497.07+4.26 (+0.86%) ▲|C143.40-1.57 (-1.08%) ▼|CAT1,000.35+16.11 (+1.64%) ▲|CL92.99+1.56 (+1.71%) ▲|CMCSA22.59-0.22 (-0.94%) ▼|COF201.81+4.00 (+2.02%) ▲|COP106.94-3.04 (-2.76%) ▼|COST961.11+3.43 (+0.36%) ▲|CRM154.33+0.91 (+0.59%) ▲|CSCO120.51-0.64 (-0.53%) ▼|CVS101.46-0.12 (-0.11%) ▼|CVX171.56-4.42 (-2.51%) ▼|DE609.73+17.79 (+3.01%) ▲|DHR187.97+9.00 (+5.03%) ▲|DIS102.29-1.24 (-1.20%) ▼|DUK125.18+0.13 (+0.10%) ▲|EMR142.20-0.94 (-0.66%) ▼|FDX313.03-4.21 (-1.33%) ▼|GD346.28-4.06 (-1.16%) ▼|GE367.55+11.08 (+3.11%) ▲|GEV1,063.92+28.94 (+2.80%) ▲|GILD125.47+0.42 (+0.34%) ▲|GM79.81+0.86 (+1.09%) ▲|GOOG347.89+1.81 (+0.52%) ▲|GOOGL348.75+2.66 (+0.77%) ▲|GS1,081.98-12.46 (-1.14%) ▼|HD340.26+15.81 (+4.87%) ▲|HON227.06+4.69 (+2.11%) ▲|IBM262.50-2.44 (-0.92%) ▼|INTC132.90+0.62 (+0.47%) ▲|INTU268.42+10.37 (+4.02%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ240.48+1.40 (+0.59%) ▲|JPM333.09-1.06 (-0.32%) ▼|KO81.24+0.93 (+1.15%) ▲|LIN521.77+9.51 (+1.86%) ▲|LLY1,109.80+2.72 (+0.25%) ▲|LMT493.50-10.17 (-2.02%) ▼|LOW220.88+7.34 (+3.44%) ▲|LRCX368.81-2.52 (-0.68%) ▼|MA493.69+5.62 (+1.15%) ▲|MCD274.21+2.55 (+0.94%) ▲|MDLZ62.15+1.09 (+1.79%) ▲|MDT80.65+0.02 (+0.02%) ▲|META560.77-1.43 (-0.25%) ▼|MMM167.73+5.89 (+3.64%) ▲|MO72.05+0.44 (+0.61%) ▲|MRK120.85+1.25 (+1.04%) ▲|MS221.35-4.69 (-2.07%) ▼|MSFT372.37-1.58 (-0.42%) ▼|MU1,037.63-14.15 (-1.34%) ▼|NEE86.79+0.36 (+0.41%) ▲|NFLX71.73-1.10 (-1.50%) ▼|NKE41.99-0.40 (-0.93%) ▼|NOW94.53-1.41 (-1.47%) ▼|NVDA199.69-0.32 (-0.16%) ▼|ORCL157.45-7.71 (-4.67%) ▼|PEP143.17+1.12 (+0.79%) ▲|PFE24.15-0.58 (-2.33%) ▼|PG153.09+2.23 (+1.47%) ▲|PLTR113.22-3.48 (-2.98%) ▼|PM178.59-0.10 (-0.06%) ▼|QCOM196.22-7.92 (-3.88%) ▼|RTX185.84-0.55 (-0.30%) ▼|SBUX103.92+2.87 (+2.84%) ▲|SCHW91.38-1.79 (-1.92%) ▼|SO94.74-0.20 (-0.21%) ▼|SPG218.90+2.16 (+1.00%) ▲|T22.41-0.41 (-1.78%) ▼|TMO489.11+19.76 (+4.21%) ▲|TMUS182.76-1.81 (-0.98%) ▼|TSLA378.32-3.29 (-0.86%) ▼|TXN303.86-0.50 (-0.16%) ▼|UBER74.45+4.78 (+6.86%) ▲|UNH406.37-2.89 (-0.70%) ▼|UNP260.55+1.94 (+0.75%) ▲|UPS105.24-0.59 (-0.56%) ▼|USB60.02-0.03 (-0.05%) ▼|V331.70+3.22 (+0.98%) ▲|VZ45.58-1.16 (-2.47%) ▼|WFC83.89-0.24 (-0.29%) ▼|WMT119.52+0.10 (+0.08%) ▲|XOM136.44-3.29 (-2.35%) ▼|
24.7 C
New York
Wednesday, June 24, 2026

Tag: pharmaceutical

newssourceFORcompanyinformationcontent1marketreleases

Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China

SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis...

Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ --...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

CODI SHAREHOLDERS: Compass Diversified Holdings Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 8 Deadline (NYSE:CODI)

Compass Diversified Holdings investors that lost money are notified to contact BFA Law before July 8, 2025 securities fraud class action deadline.

ELV SHAREHOLDERS: Elevance Health, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 11 Deadline (NYSE:ELV)

Elevance Health, Inc. investors that lost money are notified to contact BFA Law before July 11, 2025 securities fraud class action deadline.

CIVI SHAREHOLDERS: Civitas Resources, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 1 Deadline (NYSE:CIVI)

Civitas Resources, Inc. investors that lost money are notified to contact BFA Law before July 1, 2025 securities fraud class action deadline.

IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. investors that lost money are notified to contact BFA Law before July 14, 2025 securities fraud class action deadline.

FTRE SHAREHOLDERS: Fortrea Holdings Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by August 1 Deadline (NASDAQ:FTRE)

Fortrea Holdings Inc. investors that lost money are notified to contact BFA Law before August 1, 2025 securities fraud class action deadline.

URGN SHAREHOLDERS: UroGen Pharma Ltd. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 28 Deadline (NASDAQ:URGN)

UroGen Pharma Ltd. investors that lost money are notified to contact BFA Law before July 28, 2025 securities fraud class action deadline.

RDDT SHAREHOLDERS: Reddit, Inc. Investors are Reminded of the Pending Securities Fraud Investigation – Contact BFA Law (NYSE:RDDT)

Reddit, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud investigation.

OGN SHAREHOLDERS: Organon & Co. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 22 Deadline (NYSE:OGN)

Organon & Co. investors that lost money are notified to contact BFA Law before July 22, 2025 securities fraud class action deadline.

DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals’ Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints

- FDA decision anticipated within four weeks - TORONTO, June 13, 2025 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust") today announced KalVista Pharmaceuticals...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers